Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Withdrawal Study in Psoriatic Arthritis
NCT02584855Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of ixekizumab in psoriatic arthritis (PsA), sponsored by Eli Lilly and Company. Started Sep 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02584855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584855.